ESTRO 2025 - Abstract Book

S1296

Clinical - Lung

ESTRO 2025

Figure 2. Average/cumulative inter-fraction robstness

Conclusion: Our study demonstrates that NTCP can be reduced with PAT compared to IMPT, with similar inter-fraction robustness. These findings suggest that PAT may offer significant dosimetric benefits for individual NSCLC patients, supporting the need for individualized decision-making based on treatment plan comparisons.

Keywords: lung cancer, treatment planning, proton therapy

317

Digital Poster Single-center experience using moderate hypofractionation within chemoradiotherapy for limited stage small cell lung cancer Bruno E. Zambrana Moreno 1 , Beatriz Álvarez Rodríguez 1 , Emilio Sánchez Saugar 1 , Raquel Ciérvide Jurío 1 , Xin Chen Zao 1 , María del Carmen Saiz Guisasola 1 , Ovidio Hernando Requejo 1 , Ángel Montero Luis 1 , Mercedes López González 1 , Jeannette J. Valero Albarrán 1 , Mariola García-Aranda Pez 1 , Rosa Maria Alonso Gutiérrez 1 , Leyre Alonso Iracheta 2 , Alejandro Prado Barragan 2 , Pedro Fernández Letón 2 , María del Carmen Rubio Rodríguez 1 1 Radiation Oncology, HM Hospitales, Madrid, Spain. 2 Medical physics, HM Hospitales, Madrid, Spain Purpose/Objective: To evaluate the efficacy, safety and toxicity of hypofractionated radiotherapy scheme with concomitant chemotherapy for Limited Stage Small Cell Lung Cancer (LS-SCLC) based on results previously reported, currently with a 6 month updated data. Evidence published about moderate hypofractionation encouraged us to apply this treatment modality.